Fig. 1From: Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort studyImprovement in 6MWD over 24 weeks following ambrisentan treatment (LOCF) (ITT population). Note: Mean (SD) baseline value for 6MWD was 377.1 (61.30) meters. AMB: ambrisentanBack to article page